Exon skipping to treat DMD
Duchenne muscular dystrophy (DMD) is an inherited muscle disorder that is ultimately fatal. A deficiency in normal dystrophin, a structural protein that is indispensable for muscle cell function, causes severe damage to muscle cells. This dystrophin deficiency is due to mutations in the gene encoding dystrophin. Komaki et al. have now developed a morpholino antisense oligonucleotide, NS-065/NCNP-01, designed to recover dystrophin function and halt muscle damage by skipping exon 53 in the dystrophin gene. These authors report the results of a phase 1 clinical trial of NS-065/NCNP-01 conducted in 10 patients with DMD. The drug showed a favorable safety profile and pharmacokinetics, and the authors demonstrated that it effectively skipped exon 53 in the dystrophin gene, suggesting that a phase 2 trial of the drug is warranted.
- Copyright © 2018 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works
This is an article distributed under the terms of the Science Journals Default License.